in damaged spinal cords
Yale researchers have developed a synthetic peptide that promotes new nerve fiber growth in the damaged spinal cords of laboratory rats and allows them to walk better, according to a study published Thursday in the journal Nature.
The finding could lead to the reversal of functional deficits resulting from brain and spinal cord injuries, trauma and stroke, or brought about by degenerative diseases, such as multiple sclerosis.
The lead author of the study, Dr. Stephen Strittmatter, associate professor of neurology and neurobiology at the School of Medicine, says the study confirms which molecules block axon regeneration in the spinal cord and shows that a peptide can promote new growth. Axons are the "telephone lines" of the nervous system and carry a nerve impulse to a target cell.
"One of the prominent inhibitors is Nogo and we developed a way to block Nogo action with a peptide that binds to the Nogo receptor and prevents it from doing its normal job," Strittmatter says. "There is no drug used today to promote axon recovery in humans, so it is hard to predict how well this drug will work in humans."
He says the laboratory rats were administered the peptide for four weeks through a catheter inserted into the spinal canal. A number of nerve fibers did grow back and the rats were able to walk better than without the treatment.
Before moving to human trials, Strittmatter says researchers first must determine whether the synethetic peptide can promote nerve fiber growth in animals weeks and months after injury and whether the compound is effective and safe for use in humans.
"There is some reason to think that the peptide might promote growth in older injuries because some damaged nerve fibers in the brain and spinal cord just sit there," he says. "If we had some way to block these inhibitors the nerve fibers might grow back again."
The paper is the third that Strittmatter has published in Nature about this research. The first paper described the Nogo protein. The second paper detailed the receptor through which Nogo acts. This newest data demonstrates how to block the interaction and how to reverse its function pharmacologically.
Co-researchers included Tadzia GrandPre, a graduate student, and Shuxin Li, a postdoctoral fellow.
-- By Jacqueline Weaver
T H I S
Bulletin Home
W E E K ' SS T O R I E S
Yale Celebrates 301st Graduation
Biodiversity expert named new director of Peabody
Renowned architect Maya Lin elected to Yale Corporation
Two faculty members named to Sterling professorshipsDrama School/Yale Rep to receive 2002 Governor's Arts Award
Two pioneering researchers are elected to the NAS
Peptide promotes nerve growth in damaged spinal cords
Exhibit shows how publisher 'cooks up' his books
Yale to join Elm City in celebration of world's arts & ideas
Nursing school marks retirement of its former dean
Center honors former director Dr. Donald Cohen
Divinity dean Rebecca Chopp steps down
Schools of Medicine, Nursing host class reunions
Library's Franklin Papers and Fortunoff Archive win NEH grants
Undergraduates named Dean's Research Fellows
City's downtown will heat up with 'hot sounds' this summer
Yale professor granted award to study TSC
Bulldogs aim to out-row Crimsons in 150th regatta
Artist who portrays black life in the rural South to discuss his work . . .
Campus Notes
|Visiting on Campus|Calendar of Events|In the News|Bulletin Board
Yale Scoreboard|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs Home|News Releases|
E-Mail Us|Yale Home Page